Literature DB >> 17313374

Manipulation of host signalling pathways by anthrax toxins.

Benjamin E Turk1.   

Abstract

Infectious microbes face an unwelcoming environment in their mammalian hosts, which have evolved elaborate multicelluar systems for recognition and elimination of invading pathogens. A common strategy used by pathogenic bacteria to establish infection is to secrete protein factors that block intracellular signalling pathways essential for host defence. Some of these proteins also act as toxins, directly causing pathology associated with disease. Bacillus anthracis, the bacterium that causes anthrax, secretes two plasmid-encoded enzymes, LF (lethal factor) and EF (oedema factor), that are delivered into host cells by a third bacterial protein, PA (protective antigen). The two toxins act on a variety of cell types, disabling the immune system and inevitably killing the host. LF is an extraordinarily selective metalloproteinase that site-specifically cleaves MKKs (mitogen-activated protein kinase kinases). Cleavage of MKKs by LF prevents them from activating their downstream MAPK (mitogen-activated protein kinase) substrates by disrupting a critical docking interaction. Blockade of MAPK signalling functionally impairs cells of both the innate and adaptive immune systems and induces cell death in macrophages. EF is an adenylate cyclase that is activated by calmodulin through a non-canonical mechanism. EF causes sustained and potent activation of host cAMP-dependent signalling pathways, which disables phagocytes. Here I review recent progress in elucidating the mechanisms by which LF and EF influence host signalling and thereby contribute to disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17313374     DOI: 10.1042/BJ20061891

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  68 in total

Review 1.  New insights into the biological effects of anthrax toxins: linking cellular to organismal responses.

Authors:  Annabel Guichard; Victor Nizet; Ethan Bier
Journal:  Microbes Infect       Date:  2011-09-08       Impact factor: 2.700

Review 2.  Anthrax lethal and edema toxins in anthrax pathogenesis.

Authors:  Shihui Liu; Mahtab Moayeri; Stephen H Leppla
Journal:  Trends Microbiol       Date:  2014-03-27       Impact factor: 17.079

3.  Inhibition of anthrax lethal factor: lability of hydroxamate as a chelating group.

Authors:  Feng Li; Irina Chvyrkova; Simon Terzyan; Nancy Wakeham; Robert Turner; Arun K Ghosh; Xuejun C Zhang; Jordan Tang
Journal:  Appl Microbiol Biotechnol       Date:  2012-01-25       Impact factor: 4.813

4.  Selectivity of docking sites in MAPK kinases.

Authors:  A Jane Bardwell; Erlynn Frankson; Lee Bardwell
Journal:  J Biol Chem       Date:  2009-02-05       Impact factor: 5.157

5.  Inhibition of Interleukin 1β (IL-1β) Expression by Anthrax Lethal Toxin (LeTx) Is Reversed by Histone Deacetylase 8 (HDAC8) Inhibition in Murine Macrophages.

Authors:  Soon-Duck Ha; Chantelle Reid; Shahab Meshkibaf; Sung Ouk Kim
Journal:  J Biol Chem       Date:  2016-02-24       Impact factor: 5.157

Review 6.  Anti-virulence strategies to combat bacteria-mediated disease.

Authors:  David A Rasko; Vanessa Sperandio
Journal:  Nat Rev Drug Discov       Date:  2010-01-18       Impact factor: 84.694

7.  Increased catalytic efficiency following gene fusion of bifunctional methionine sulfoxide reductase enzymes from Shewanella oneidensis.

Authors:  Baowei Chen; Lye Meng Markillie; Yijia Xiong; M Uljana Mayer; Thomas C Squier
Journal:  Biochemistry       Date:  2007-11-13       Impact factor: 3.162

8.  Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.

Authors:  Crystal L Loving; Taruna Khurana; Manuel Osorio; Gloria M Lee; Vanessa K Kelly; Scott Stibitz; Tod J Merkel
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

9.  Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.

Authors:  Ludovic Bannwarth; Allison B Goldberg; Catherine Chen; Benjamin E Turk
Journal:  Chem Biol       Date:  2012-07-27

10.  Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.

Authors:  Yong Sung Park; Jin Hyup Lee; Chien-Fu Hung; T-C Wu; Tae Woo Kim
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.